ISM4525 is an orally available DGKA inhibitor with high selectivity in cancer immunotherapy. (IMAGE)

InSilico Medicine

ISM4525 is an orally available DGKA inhibitor with high selectivity in cancer immunotherapy.

Caption

Insilico managed to achieve additional unique molecules with favorable properties by updating Chemistry42 3.0 with ADMET prediction and reward customization features. In addition, PandaOmics 4.0 was used for expanding indications, discovering potential combination strategies and better patient screening. Following additional preclinical studies, Insilico nominated the novel second-generation inhibitor targeting DGKA for the wholly-owned program in December 2023.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.